查詢結果分析
來源資料
相關文獻
- Comparative Analysis of Treatment Result in Advanced Hypopharyngeal Cancer: Chemoradiotherapy Alone or Surgery Followed by Chemoradiotherapy
- Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Hypopharyngeal Cancer
- 晚期下咽癌之治療經驗
- 局部廣泛性食道癌--手術後同步化學放射治療
- The Effect and Safety of Transdermal Fentanyl for Concurrent Chemoradiation Therapy-Induced Mucositis Pain in Head and Neck Cancer Patients
- Defunctioning Stoma in Locally Advanced Rectal Cancer Receiving Concurrent Chemoradiotherapy and Low Anterior Resection
- Long-term Remission of Advanced Esthesioneuroblastoma after Chemoradiotherapy
- Concurrent Weekly Cisplatin and Radiotherapy Plus Adjuvant Chemotherapy for Nasopharyngeal Cancer--A Preliminary Study
- Preliminary Results of Preoperative Chemoradiation Therapy for Cervical Esophageal Squamous Cell Carcinoma with Larynx Preservation
- 術前同步化學放射治療合併手術切除成功治療局部進行期結腸癌
頁籤選單縮合
題 名 | Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Hypopharyngeal Cancer=下咽癌接受化學放射治療或單純放射治療的結果比較 |
---|---|
作 者 | 洪世凱; 陳泓里; 謝忱希; 許文林; 張國華; 陳裕仁; 李文星; | 書刊名 | 中華放射線醫學雜誌 |
卷 期 | 31:2 民95.04 |
頁 次 | 頁77-84 |
分類號 | 416.89 |
關鍵詞 | 同步化學放射治療; 下咽癌; 放射治療; Concurrent chemoradiation; Hypopharyngeal carcinoma; Radiotherapy; |
語 文 | 英文(English) |
中文摘要 | 評估局部進展性下咽癌接受化學放射治療或單純放射治療的結果比較。 從1988 年十二月到2004 年十二月共有74 位局部進展性的病人符合臨床分期第三或者第四期的條件。其中38 位病人接受同步化學放射治療及全身性的化學治療,其餘36 位病人接受單純放射治療。同步化學治療為每週一次低劑量的cisplatin (30 mg/m2),共8次。間隔3到4週後,給予全身性的化學治療。設計劑量為每月一次,每次cisplatin (20 mg/m2)加5-FU (1000 mg/m2)D1~D5,共4次。在不同治療的組別,放射治療的劑量設計均為7020-7560 cGy 。研究的結果紀錄存活及毒性。 這兩組病患的T與N分期在分佈上並無明顯差異。對於同步化學放射治療組別的患者,其中中位存活時間、5年存活率及無病存活率分別為23 個月、28% 及23% 。其中有75% 的患者發生局部復發,而遠端轉移發生在24% 的患者身上。對於單純放射治療組別的患者,其中中位存活時間及5年存活率分別為16 個月及7% 。其中有86% 的患者發生局部復發,而遠端轉移發生在28% 的患者身上。治療結果在這兩個組別,對於5年存活率、無病存活率、局部控制有明顯差異。在不同治療的組別均發現超過70 Gy 的患者有較好的存活率及局部控制。 根據此回溯性研究,同步化學放射治療的結果比單純放射治療好。為了增加較好的存活率及局部控制,放射治療的劑量至少應給予70 Gy 。 |
英文摘要 | The purpose of this retrospective study is to compare the treatment results of locally advanced hypopharyngeal carcinoma with two different pro-tocols. From December 1988 to December 2004, the records of 74 patients with locally advanced (stage III/IV) hypopharyngeal cancer treated at 2 cen-ters were reviewed. Thirty-eight patients had been treated with concurrent chemoradiation (CCRT) followed by adjuvant systemic chemotherapy and 36 patients with radiation alone (RT) . CCRT consisted of weekly cisplatin 30 mg/m2 as a radiosensitizer and plus systemic adjuvant chemotherapy with four monthly cycles of cisplatin 20 mg/m2 and 5-fluoro-uracil 1000 mg/m2 for five consecutive days. The radiotherapy was arranged in a dose of 70.2 to 75.6 Gy for the both groups. The study end points included outcome and toxicity. There was no significant difference in T and N staging between the two groups. The median sur-vival for the CCRT group was 23.0 months, with the estimated 5-year overall survival and disease free survival being 28% and 23%, respectively. Local regional failure occurred in 75% of patients and 24% of patients developed distant metas-tasis. For the RT group, median survival was 16.0 months with the estimated 5-year overall survival being 7%. Local regional failure occurred in 86% of patients and 28% of patients developed distant metastasis. There were significant differences between the two groups (CCRT vs. RT) in terms of overall survival, disease-free survival and local control (p < 0.05) . A higher dose of radiation (>70 Gy) resulted in significantly better survival and local control in the CCRT or RT group (p < 0.05) . CCRT seems to be a better option for advanced hypopharyngeal cancer treatment because of better survival and local control than RT alone. In order to achieve acceptable local control and survival, a high dose of radiation (>70 Gy) should be given. |
本系統中英文摘要資訊取自各篇刊載內容。